Molecular mechanisms of vascular smooth muscle cell growth

Current Opinion in Cardiology

Volumn 12, Issue 6, 1997, Pages 495-503

  Hafizi, Sassan ^a   Chester, Adrian H ^a   Yacoub, Magdi H ^a  

^a HAREFIELD HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOTRANSFERASE; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN KINASE; PROTEIN KINASE B; UNCLASSIFIED DRUG;

CELL CYCLE; CELL DIVISION; CELL GROWTH; CELL PROLIFERATION; MEDIATOR; MOLECULAR BIOLOGY; PRIORITY JOURNAL; RECEPTOR BINDING; REVIEW; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE;

EID: 0030729397     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001573-199711000-00001     Document Type: Review

References (65)

1. Newby AC, George SJ: Proposed roles for growth factors in mediating smooth muscle proliferation in vascular pathologies. Cardiovasc Res 1993, 27:1173-1183.
2. Nilsson J: Cytokines and smooth muscle cells in atherosclerosis. Cardiovasc Res 1993, 27:1184-1190.
3. Predel HG, Yang Z, von Segesser L, Turina M, Buhler FR, Lüscher TF: Implications of pulsatile stretch on growth of saphenous vein and mammary artery smooth muscle. Lancet 1992, 340:878-879.
4. Rao GN, Berk BC: Active oxygen species stimulate vascular smooth muscle cell growth and proto-oncogene expression. Circ Res 1992, 70:593-599.
5. + exchange and growth factors in pulmonary artery smooth muscle cell proliferation. Am J Respir Cell Mol Biol 1996, 14:139-145.
6. Murphy TJ, Alexander RW, Griendling KK, Runge MS, Bernstein KE: Isolation of a cDNA encoding the vascular type-1 angiotensin II receptor. Nature 1991, 351:233-236.
7. Molloy CJ, Taylor DS, Weber H: Angiotensin II stimulation of rapid protein tyrosine phosphorylation and protein kinase activation in rat aortic smooth muscle cells. J Biol Chem 1993, 268:7338-7345.
8. Duff JL, Berk BC, Corson MA: Angiotensin II stimulates the pp44 and pp42 mitogen-activated protein kinases in cultured rat aortic smooth muscle cells. Biochem Biophys Res Commun 1992, 188:257-264.
9. Mu S, Khalil RA, Morgan KG, Ware JA, Kent KC: Mitogen-activated protein kinase and proliferation of human vascular smooth muscle cells. Am J Physiol 1996, 270:H142-H150. A significant investigation comparing the effects of a range of agents on human VSMC proliferation and on intracellular signaling, in terms of tyrosine phosphorylation and MAPK activation.
10. 2+ mobilization and protein kinase C activation. J Biol Chem 1989, 264:526-530.
11. Leduc I, Haddad P, Giasson E, Meloche S: Involvement of a tyrosine kinase pathway in the growth-promoting effects of angiotensin II on aortic smooth muscle cells. Mol Pharmacol 1995, 48:582-592.
12. c-src in vascular smooth muscle cells. Circ Res 1995, 77:1053-1059.
13. Linseman DA, Benjamin CW, Jones DA: Convergence of angiotensin II and platelet-derived growth factor receptor signaling cascades in vascular smooth muscle cells. J Biol Chem 1995, 270:12,563-12,568.
14. 2-terminal kinase groups of mitogen-activated protein kinases. J Biol Chem 1996, 271:5750-5754.
15. Geisterfer AA, Peach MJ, Owens GK: Angiotensin II induces hypertrophy, not hyperplasia, of cultured rat aortic smooth muscle cells. Circ Res 1988, 62:749-756.
16. Berk BC, Vekshtein V, Gordon HM, Tsuda T: Angiotensin II-stimulated protein synthesis in cultured vascular smooth muscle cells. Hypertension 1989, 13:305-314.
17. Hafizi S, Chester AH, Yacoub MH: Mitogenic response of cultured human coronary artery vascular smooth muscle cells (VSMC) [abstract]. Eur J Clin Invest 1996, 26:A6.
18. Liao D, Monia B, Dean N, Berk BC: Protein kinase C-ς mediates angiotensin II activation of ERK1/2 in vascular smooth muscle cells. J Biol Chem 1997, 272:6146-6150. This study provides evidence for a fundamental difference between early signaling by PDGF and ANG II, showing relative use of two different proteins to activate the ERK pathway, which may partly explain the difference in the growth responses induced by the two agents.
19. Davis RJ: The mitogen-activated protein kinase signal transduction pathway. J Biol Chem 1993, 268:14,553-14,556.
20. Force T, Pombo CM, Avruch JA, Bonventre JV, Kyriakis JM: Stress-activated protein kinases in cardiovascular disease. Circ Res 1996, 78:947-953.
21. 2-terminal kinase in cultured cardiac myocytes of neonatal rats. Circ Res 1997, 80:139-146.
22. Mansour SJ, Matten WT, Hermann AS, Candia JM, Rong S, Fukasawa K, Vande Woude GF, Ahn NG: Transformation of mammalian cells by constitutively active MAP kinase kinase. Science 1994, 265:966-970.
23. Alessi DR, Cuenda A, Cohen P, Dudley DT, Saltiel AR: PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J Biol Chem 1995, 270:27489-27494.
24. Daum G, Hedin U, Wang Y, Wang T, Clowes AW: Diverse effects of heparin on mitogen-activated protein kinase-dependent signal transduction in vascular smooth muscle cells. Circ Res 1997, 81:17-23.
25. Gille H, Kortenjann M, Thomae O, Moomaw C, Slaughter C, Cobb MH, Shaw PE: ERK phosphorylation potentiates Elk-1-mediated ternary complex formation and transactivation. EMBO J 1995, 14:951-962.
26. rsk phosphorylation and S6 phosphotransferase activity in Swiss 3T3 cells by growth factor-, phorbol ester-, and cyclic AMP-mediated signal transduction. Mol Cell Biol 1991, 11:1861-1867.
27. Xing J, Ginty DD, Greenberg ME: Coupling of the RAS-MAPK pathway to gene activation by RSK2, a growth factor-regulated CREB kinase. Science 1996, 273:959-963. Little is known about how signaling pathways such as the MAPK cascade couple to actual gene regulation, and this study identifies RSK2 as a mediator in achieving this.
28. Chen RH, Sarnecki C, Blenis J: Nuclear localization and regulation of erk- and rsk-encoded protein kinases. Mol Cell Biol 1992, 12:915-927.
29. Marx SO, Jayaraman T, Go LO, Marks AR: Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. Circ Res 1995, 76:412-417.
30. Giasson E, Meloche S: Role of p70 S6 protein kinase in angiotensin II-induced protein synthesis in vascular smooth muscle cells. J Biol Chem 1995, 270:5225-5231.
31. Terada N, Patel HR, Takase K, Kohno K, Nairn AC, Gelfand EW: Rapamycin selectively inhibits translation of mRNAs encoding elongation factors and ribosomal proteins. Proc Natl Acad Sci U S A 1994, 91:11,477-11,481.
32. Nielsen FC, Østergaard L, Nielsen J, Christiansen J: Growth-dependent translation of IGF-II mRNA by a rapamycin-sensitive pathway. Nature 1995, 377:358-362.
33. Chung J, Kuo CJ, Crabtree GR, Blenis J: Rapamycin-FKBP specifically blocks growth-dependent activation and signaling by the 70 kd S6 protein kinases. Cell 1992, 69:1227-1236.
34. s6k: Mechanism of activation and role in mitogenesis. Semin Cancer Biol 1994, 5:255-260.
35. Flynn A, Proud CG: The role of elF4 in cell proliferation. Cancer Surv 1996, 27:293-310.
36. Beretta L, Gingras AC, Svitkin YV, Hall MN, Sonenberg N: Rapamycin blocks the phosphorylation of 4E-BP1 and inhibits cap-dependent initiation of translation. EMBO J 1996, 15:658-664.
37. Fleurent M, Gingras A, Sonenberg N, Meloche S: Angiotensin II stimulates phosphorylation of the translational repressor 4E-binding protein 1 by a mitogen-activated protein kinase-independent mechanism. J Biol Chem 1997, 272:4006-4012. The demonstration of 4E-BP1 phosphorylation, and hence regulation of translation in VSMC by ANG II, provides good evidence for a mechanism by which a vasoconstrictive agent such as ANG II may also induce VSMC growth, in this case hypertrophy.
38. Haystead TAJ, Haystead CMM, Hu C, Lin T, Lawrence Jr JC: Phosphorylation of PHAS-I by mitogen-activated protein (MAP) kinase: identification of a site phosphorylated by MAP kinase in-vitro and in response to insulin in rat adipocytes. J Biol Chem 1994, 269:23,185-23,191.
39. s6k and MAPK pathways, in this case regarding the phosphorylation of 4E-BP1.
40. Domin J, Dhand R, Waterfield MD: Binding to the platelet-derived growth factor receptor transiently activates the p85αp110α phosphoinositide 3-kinase complex in vivo. J Biol Chem 1996, 271:21,614-21,621.
41. Hawes BE, Luttrell LM, van Biesen T, Lefkowitz RJ: Phosphatidylinositol 3-kinase is an early intermediate in the Gβγ-mediated mitogen-activated protein kinase signaling pathway. J Biol Chem 1996, 271:12,133-12,136.
42. Panek RL, Dahring TK, Olszewksi BJ, Keiser JA: PDGF receptor protein tyrosine kinase expression in the balloon-injured rat carotid artery. Arterioscler Thromb Vasc Biol 1997, 17:1283-1288. The special significance of this investigation is that PI3-K, a molecule that has only recently come to the fore as an important signaling mediator, was shown to be activated in this in vivo model of injury-induced restenosis.
43. Saward L, Zahradka P: Angiotensin II activates phosphatidylinositol 3-kinase in vascular smooth muscle cells. Circ Res 1997, 81:249-257. A novel finding: in addition to growth factor receptors, a G protein-coupled receptor agonist such as ANG II can also activate PI3-K in VSMC. Use of the PI3-K inhibitors demonstrates the importance of this molecule in growth.
44. Marte BM, Rodriguez-Viciana P, Wennstrom S, Warne PH, Downward J: R-Ras can activate the phosphoinositide 3-kinase but not the MAP kinase arm of the Ras effector pathways. Curr Biol 1997, 7:63-70.
45. Cheatham B, Vlahos CJ, Cheatham L, Wang L, Blenis J, Kahn CR: Phosphatidylinositol 3-kinase activation is required for insulin stimulation of pp70 S6 kinase, DNA synthesis, and glucose transporter translocation. Mol Cell Biol 1994, 14:4902-4911.
46. Suga J, Yoshimasa Y, Yamada K, Yamamoto Y, Inoue G, Okamoto M: Differential activation of mitogen-activated protein kinase by insulin and epidermal growth factor in 3T3-L1 adipocytes: a possible involvement of PI3-kinase in the activation of the MAP kinase by insulin. Diabetes 1997, 46:735-741.
47. Bos JL: A target for phosphoinositide 3-kinase: Akt/PKB. Trends Biochem Sci 1995, 20:441-442.
48. Stokoe D, Stephens LR, Copeland T, Gaffney PRJ, Reese CB, Painter GF, Holmes AB, McCormick F, Hawkins PT: Dual role of phosphatidylinositol-3,4,5-trisphosphate in the activation of protein kinase B. Science 1997, 277:567-570.
49. Alessi DR, James SR, Downes CP, Holmes AB, Gaffney PRJ, Reese CB, Cohen P: Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Bα. Curr Biol 1997, 7:261-269.
50. Kauffmann-Zeh A, Rodriguez-Viciana P, Ulrich E, Gilbert C, Coffer P, Downward J, Evan G: Suppression of c-Myc-induced apoptosis by Ras signalling through PI(3)K and PKB. Nature 1997, 385:544-548.
51. Burgering BMT, Coffer PJ: Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction. Nature 1995, 376:599-602.
52. Ikeda M-A, Jakoi L, Nevins JR: A unique role for the Rb protein in controlling E2F accumulation during cell growth and differentiation. Proc Natl Acad Sci U S A 1996, 93:3215-3220.
53. Ohtani K, DeGregori J, Nevins JR: Regulation of the cyclin E gene by transcription factor E2F1. Proc Natl Acad Sci U S A 1995, 92:12146-12150.
54. Haffner R, Oren M: p53: biochemical properties and biological effects of p53. Curr Opin Genet Dev 1995, 5:84-90.
55. Speir E, Modali R, Huang E-S, Leon MB, Shawl F, Finkel T, Epstein SE: Potential role of human cytomegalovirus and p53 interaction in coronary restenosis. Science 1994, 265:391-394.
56. Dynlacht BD. Regulation of transcription by proteins that control the cell cycle. Nature 1997, 389:149-152.
57. Kip1 for restriction point control of the fibroblast cell cycle. Science 1996, 272:877-880.
58. Kip1.
59. Owens GK, Geisterfer AA, Yang YW, Komoriya A: Transforming growth factor-beta-induced growth inhibition and cellular hypertrophy in cultured vascular smooth muscle cells. J Cell Biol 1988, 107:771-780.
60. Reynisdóttir I, Polyak K, Iavarone A, Massagué J: Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-β. Genes Dev 1995, 9:1831-1845.
61. Grainger DJ, Kemp PR, Metcalfe JC, Liu AC, Lawn RM, Williams NR, Grace AA, Schofield PM, Chauhan A: The serum concentration of active transforming growth factor-β is severely depressed in advanced atherosclerosis. Nature Med 1995, 1:74-79.
62. 1 transition in vascular smooth muscle cells. Mol Cell Biol 1993, 13:3722-3733.
63. Morishita R, Gibbons G, Ellison K, Nakajima M, Zhang L, Kaneda Y, Ogihara T, Dzau V: Single intraluminal delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of intimal hyperplasia. Proc Natl Acad Sci U S A 1993, 90:8474-8478.
64. 1 progression. Nature 1993, 363:170-172.
65. Lee W-S, Harder JA, Yoshizumi M, Lee M-E, Haber E: Progesterone inhibits arterial smooth muscle cell proliferation. Nature Med 1997, 3:1005-1009. A new and clinically relevant finding, demonstrating the mediation of the effect of progesterone by its influence on cell cycle regulation, specifically expression of cyclins.